Current medical landscapes in Australia and New Zealand exhibit significant systemic challenges regarding the procurement of stem cell transplants and access to advanced immunotherapy for blood cancer patients.

目前澳洲與紐西蘭的醫療環境在獲取幹細胞移植以及血癌患者使用先進免疫療法方面，面臨著顯著的系統性挑戰。

The Australian stem cell donor registry has experienced a quantitative decline, decreasing from approximately 173,000 registrants in 2009 to 165,000 in 2024. This deficit is particularly acute within the 18-to-25-year-old demographic, where registration is limited to 1.2 percent. Chris Tanti, Chief Executive of the Leukaemia Foundation, attributes this shortfall to insufficient public awareness and the persistence of misconceptions regarding the invasive nature of the donation process. Consequently, Australia maintains a high dependency on international registries, specifically Germany, for 80 percent of its transplants. However, this reliance is problematic for patients of diverse ethnic backgrounds, including First Nations people, for whom domestic donor expansion is critical for genetic compatibility.

澳洲的幹細胞捐贈者登記人數有所下降，從 2009 年的大約 173,000 人減少至 2024 年的 165,000 人。此不足在 18 至 25 歲的年齡層中尤為嚴重，登記率僅為 1.2%。白血病基金會（Leukaemia Foundation）執行長 Chris Tanti 將此缺口歸因於公眾意識不足，以及對捐贈過程侵入性的誤解依然存在。因此，澳洲有 80% 的移植依賴國際登記庫，特別是德國。然而，這種依賴對於不同種族背景的患者（包括原住民）而言極具問題，對他們來說，擴大國內捐贈者規模對於基因相容性至關重要。

Parallel systemic constraints are evident in New Zealand regarding the availability of Chimeric Antigen Receptor (CAR) T-cell therapy. Currently, this modality is accessible only via the Enable clinical trial conducted by the Malaghan Institute of Medical Research. The complexity and prohibitive costs of the therapy—estimated between $500,000 and $1 million—preclude its integration into the public health system. This fiscal barrier necessitates private fundraising for patients who are ineligible for domestic trials due to rapid disease progression or the requirement for alternative immunotherapies. Nicola Coom of the Cancer Society New Zealand has noted that the current framework forces a dichotomy between financial stability and the acquisition of potentially curative medical interventions.

紐西蘭在 CAR-T 細胞療法（嵌合抗原受體 T 細胞療法）的可用性方面也面臨著平行系統性限制。目前，此療法僅能透過 Malaghan 醫學研究所進行的 Enable 臨床試驗獲取。該療法的複雜性與高昂成本（估計在 50 萬至 100 萬美元之間）使其無法整合至公共衛生體系。這種財政障礙使得部分患者因疾病進展迅速或需要替代免疫療法而無法參加國內試驗，必須依賴私人籌款。

Furthermore, the clinical trajectory of patients is often complicated by diagnostic delays. Instances of misdiagnosis have led to the administration of unnecessary chemotherapy and the postponement of critical interventions. The Leukaemia Foundation reports a 79 percent increase in blood cancer incidence over two decades, yet research investment in early detection and prevention remained at 12 percent between 2012 and 2020. To mitigate these trends, the Foundation has proposed a government investment of $125 million to enhance research and diagnostic capabilities.

此外，患者的臨床進程經常因診斷延遲而複雜化。誤診案例導致了不必要的化療以及關鍵干預措施的推遲。白血病基金會報告稱，過去二十年血癌發病率增加了 79%，但 2012 年至 2020 年間，早期偵測與預防的研究投資率僅維持在 12%。為了緩解這些趨勢，基金會建議政府投資 1.25 億美元，以強化研究與診斷能力。

The region continues to face critical shortages in donor registries and equitable access to high-cost therapies, necessitating systemic reform and increased funding.

該地區持續面臨捐贈者登記嚴重短缺以及高成本療法獲取不公平的問題，亟需系統性改革與增加資金投入。